New research published in the Journal of the American Medical Association highlights a lack of substantial evidence supporting the medicinal use of cannabis, especially for pain, anxiety, and insomnia. Aiming to review the scientific data behind the claims of cannabis benefits, the study suggests that while millions of Americans use cannabis for medical purposes, the findings do not support its widespread effectiveness.
Read More
Dr. Kevin Hill, director of the Division of Addiction Psychiatry at Beth Israel Deaconess Medical Center, contributed to the research, describing it as the most comprehensive review available. He noted that while there are certain conditions, such as nausea from cancer treatments, where cannabis and its active compounds can be beneficial, the overall evidence for its efficacy in treating common ailments is limited. Hill also highlighted potential risks associated with cannabis use, including cardiovascular issues and the possibility of addiction, urging patients and doctors to explore alternative treatments.
"We hope our review will foster sensible, evidence-based discussions between clinicians and patients, guiding them towards proven therapies," Hill said.
The study's findings are particularly relevant in the context of cannabis's federal classification as an illegal drug, which has hindered research efforts. Despite this, over half of the states and the District of Columbia have legalized cannabis, resulting in a booming industry worth tens of billions of dollars. Hill pointed out that the financial stake involved in cannabis sales presents a unique opportunity for cannabis businesses and states to fund further scientific research.
According to the study, 27% of adults in the U.S. and Canada have used cannabis for medical reasons at some point, with over 10% of the U.S. population reporting the use of cannabidiol (CBD) for therapeutic purposes. While the review acknowledges some legitimate medical applications of FDA-approved cannabis for treating nausea, appetite stimulation in cancer patients, and certain seizures, Hill cautioned that the overall evidence currently leans heavily towards demonstrating more risks than benefits.